Cefixime vs Ciprofloxacin for Acute Uncomplicated Cystitis: Clinico-Economic Study | CMAC

Cefixime vs Ciprofloxacin for Acute Uncomplicated Cystitis: Clinico-Economic Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(1):59-66

Type
Journal article

Objective.

To evaluate clinico-economical effectiveness of short course of cefixime and ciprofloxacin in women with acute uncomplicated cystitis.

Materials and Methods.

A prospective randomized clinico-economic study of effectiveness of cefixime and ciprofloxacin in 104 patients with acute uncomplicated cystitis.

Results.

At visit 2 (day 8) microbiological cure rates were detected in 95.9%, 55.6% and 71.4% of patients from Group 1 (cefixime), Group 2-a (ciprofloxacin 250 mg BID) and Group 2-b (ciprofloxacin 500 mg BID), respectively. The direct costs were 2935.6 RUR (ciprofloxacin 500 mg BID), 3096.8 RUR (cefixime 400 mg once a day) and 4048 RUR (ciprofloxacin 250 mg BID). The «costeffectiveness» rate for each treatment regimen (RUR / 1% eradication), was 7280.6, 4111.5 and 3229.2 for ciprofloxacin (250 mg), ciprofloxacin (500 mg) and cefixime (400 mg), respectively.

Conclusions.

Cefixime (400 mg once a day 5 days) is more microbiologicaly effective compare to ciprofloxacin (250–500 mg BID 5 days) in patients with acute uncomplicated cystitis. Short course of cefixime is more cost-effective than short course of ciprofloxacin (250–500 mg BID) in patients with acute uncomplicated cystitis.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared